Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. is a prominent point-of-care diagnostics company established in 1986, with a focus on delivering rapid and accurate disease tests such as STIs and COVID-19. The company's FDA CLIA Waiver for the rapid point-of-care combination test for HIV & Syphilis marks a significant milestone. Chembio's DPP® technology platform, known for its high-quality and rapid results, caters to a wide range of applications beyond infectious diseases. With global distribution to various healthcare entities, including hospitals, clinics, and public health organizations, Chembio offers a comprehensive range of diagnostic solutions. The DPP platform's ability to provide up to eight distinct test results from a single patient sample, combined with the convenience of the DPP Micro Reader optical analyzer, positions Chembio as an innovative player in the decentralized testing space. The company's dedication to expediting diagnosis and treatment aligns with the growing demand for accessible and efficient healthcare solutions. For more information, visit www.chembio.com.